Zenas Biopharma, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations

Market Cap $39.28M
PE -0
Debt $NaN
Cash $360.13M
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$87.87M
ROE	-24%
Equity	$359.44M
Growth Stability	1
PE	-0.45
PB	0.11
Price/Cash	9.17
Earnings Growth YoY	129%
Earnings Growth QoQ	75%

Market Cap	$39.28M
Assets	$403.43M
Cash	$360.13M
Shares Outstanding	3.62M
Working Capital	349.78M
Current Ratio	8.95
Equity Growth QoQ	-224%
Equity Growth YoY	-250%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Our lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We are developing obexelimab for patients in several autoimmune diseases.

SEC Filings

Direct access to Zenas Biopharma, Inc. (ZBIO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30

Sector Comparison

How does Zenas Biopharma, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Zenas Biopharma, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Zenas Biopharma, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Zenas Biopharma, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	TTM
Net Margins	-
ROA	-
ROE	-24%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	TTM
Debt over FCF	-
Debt over Equity	-
Growth Stability	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	CAGR 5Y
Revenue YoY growth	-
Earnings YoY growth	-
Equity YoY growth	-
FCF YoY growth	-